Nanotechnology in interventional cardiology: A state-of-the-art review

Almas, Talal; Haider, Rakhshan; Malik, Jahanzeb; Mehmood, Asim; Alvi, Areej; Naz, Hifza; Satti, Danish Iltaf; Zaidi, Syed Muhammad Jawad; Alsubai, Abdulla K.; AlNajdi, Sara; Alsufyani, Reema; Ramtohul, Rahul Krylov; Almesri, Abdullah; Alsufyani, Majid; Al-Bunnia, Abdulaziz H.; Alghamdi, Haitham Ahmed S.; Sattar, Yasar; Alraies, M. Chadi; Raina, Sameer

doi:10.1016/j.ijcha.2022.101149

Cited by 9 publications

(6 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanotechnology is also being investigated as a potential way to non-invasively diagnose and monitor cardiovascular diseases. Nanoparticles can be designed to bind to specific molecules or cells associated with cardiovascular diseases, allowing for the detection of these diseases with greater sensitivity and specificity than current diagnostic approaches [141].…”

Section: Nanotechnologymentioning

confidence: 99%

Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2024

J Clin Cardiol

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide. Effective prevention and management strategies are essential to reduce the burden of CVDs. This review summarizes recent advances in the prevention and management of CVDs. In terms of prevention, lifestyle modifications, such as diet, exercise, and smoking cessation, remain important strategies. Pharmacological interventions, including statins, antiplatelet agents, and antihypertensive medications, have also shown benefits. Innovative approaches, such as genetic testing and risk stratification, targeted prevention strategies, and the use of mobile health technology, are being explored. In terms of management, acute management strategies, such as reperfusion therapy for myocardial infarction, acute heart failure management, and stroke management, have improved outcomes. Chronic management strategies, including medical therapy for heart failure, arrhythmia management, and device therapy for heart failure, have also shown benefits. Innovative approaches, such as precision medicine and personalized treatment, the use of artificial intelligence in diagnosis and treatment, and advances in traditional Chinese and regenerative medicine, are being investigated. While recent advances in the prevention and management of CVDs are promising, challenges remain in implementing these strategies, including cost-effectiveness, access to care, and resistance to change in clinical practice. Continued research and innovation are essential to reduce the burden of CVDs and improve patient outcomes.

show abstract

Section: Nanotechnologymentioning

confidence: 99%

Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2024

J Clin Cardiol

View full text Add to dashboard Cite

show abstract

“…In the scope of optical imaging, fluorescent materials for labeling, including nano fluorescent probes, have been widely applied to develop optical imaging technology, providing new approaches for early monitoring and treatment of some diseases, such as cancers [49][50][51]. Given the high spatiotemporal resolution as well as the high sensitivity of optical techniques in comparison with other imaging platforms, the application of optical nanoparticles in cardiovascular research has been gradually increasing, as comprehensively reviewed by several recent articles [52][53][54]. As for atherosclerotic studies, optical imaging nanoprobes have multiple advantages for plaque detection, for example, high contrast agent sensitivity, and probe versatility.…”

Section: Optical Imaging Nanoprobes In Atherosclerotic Researchmentioning

confidence: 99%

Engineering molecular nanoprobes to target early atherosclerosis: Precise diagnostic tools and promising therapeutic carriers

Zan¹,

An²,

Wu³

et al. 2023

Nanotheranostics

View full text Add to dashboard Cite

Atherosclerosis, an inflammation-driven chronic blood vessel disease, is a major contributor to devastating cardiovascular events, bringing serious social and economic burdens. Currently, non-invasive diagnostic and therapeutic techniques in combination with novel nanosized materials as well as established molecular targets are under active investigation to develop integrated molecular imaging approaches, precisely visualizing and/or even effectively reversing early-stage plaques. Besides, mechanistic investigation in the past decades provides many potent candidates extensively involved in the initiation and progression of atherosclerosis. Recent hotly-studied imaging nanoprobes for detecting early plaques mainly including optical nanoprobes, photoacoustic nanoprobes, magnetic resonance nanoprobes, positron emission tomography nanoprobes, and other dual- and multi-modality imaging nanoprobes, have been proven to be surface functionalized with important molecular targets, which occupy tailored physical and biological properties for atherogenesis. Of note, these engineering nanoprobes provide long blood-pool residence and specific molecular targeting, which allows efficient recognition of early-stage atherosclerotic plaques and thereby function as a novel type of precise diagnostic tools as well as potential therapeutic carriers of anti-atherosclerosis drugs. There have been no available nanoprobes applied in the clinics so far, although many newly emerged nanoprobes, as exemplified by aggregation-induced emission nanoprobes and TiO 2 nanoprobes, have been tested for cell lines in vitro and atherogenic animal models in vivo , achieving good experimental effects. Therefore, there is an urgent call to translate these preclinical results for nanoprobes into clinical trials. For this reason, this review aims to give an overview of currently investigated nanoprobes in the context of atherosclerosis, summarize relevant published studies showing applications of different kinds of formulated nanoprobes in early detection and reverse of plaques, discuss recent advances and some limitations thereof, and provide some insights into the development of the new generation of more precise and efficient molecular nanoprobes, with a critical property of specifically targeting early atherosclerosis.

show abstract

“…However, this hydrogel requires a longer-term study as it showed only partial degradation in vivo after 5 weeks [ 197 ]. These notes provide the rationale to promote the development of drug-delivering materials able to degrade over time, such as bioresorbable scaffolds, in order to reduce side effects [ 198 ]. Despite nanotechnologies and biomaterials are promising therapeutic tools, they still have some limitations due to high costs and safety problems [ 199 ].…”

Section: Apj Peptide Agonistsmentioning

confidence: 99%

APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure

et al. 2023

View full text Add to dashboard Cite

The widely expressed G protein-coupled apelin receptor (APJ) is activated by two bioactive endogenous peptides, apelin and ELABELA (ELA). The apelin/ELA-APJ-related pathway has been found involved in the regulation of many physiological and pathological cardiovascular processes. Increasing studies are deepening the role of the APJ pathway in limiting hypertension and myocardial ischaemia, thus reducing cardiac fibrosis and adverse tissue remodelling, outlining APJ regulation as a potential therapeutic target for heart failure prevention. However, the low plasma half-life of native apelin and ELABELA isoforms lowered their potential for pharmacological applications. In recent years, many research groups focused their attention on studying how APJ ligand modifications could affect receptor structure and dynamics as well as its downstream signalling. This review summarises the novel insights regarding the role of APJ-related pathways in myocardial infarction and hypertension. Furthermore, recent progress in designing synthetic compounds or analogues of APJ ligands able to fully activate the apelinergic pathway is reported. Determining how to exogenously regulate the APJ activation could help to outline a promising therapy for cardiac diseases.

show abstract

Nanotechnology in interventional cardiology: A state-of-the-art review

Cited by 9 publications

References 121 publications

Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention

Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention

Engineering molecular nanoprobes to target early atherosclerosis: Precise diagnostic tools and promising therapeutic carriers

APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure

Contact Info

Product

Resources

About